-
Loading metrics
Open Access
Peer-reviewed
Research Article
FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors
-
Martin Neumann,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Ebru Coskun,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Lars Fransecky,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Liliana H. Mochmann,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Isabelle Bartram,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Nasrin Farhadi Sartangi,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Sandra Heesch,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Nicola Gökbuget,
Affiliation Goethe University Hospital, Department of Medicine II, Hematology and Oncology, Frankfurt/Main, Germany
⨯ -
Stefan Schwartz,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Christian Brandts,
Affiliation Goethe University Hospital, Department of Medicine II, Hematology and Oncology, Frankfurt/Main, Germany
⨯ -
Cornelia Schlee,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Rainer Haas,
Affiliation Department of Hematology and Oncology, University of Düsseldorf, Düsseldorf, Germany
⨯ -
Ulrich Dührsen,
Affiliation Department of Hematology and Oncology, University of Essen, Essen, Germany
⨯ -
Martin Griesshammer,
Affiliation Department of Hematology and Oncology, Klinikum Minden, Minden, Germany
⨯ -
Hartmut Döhner,
Affiliation Department of Internal Medicine III, University of Ulm, Ulm, Germany
⨯ -
Gerhard Ehninger,
Affiliation Department of Hematology and Oncology, University of Dresden, Dresden, Germany
⨯ -
Thomas Burmeister,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Olga Blau,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Eckhard Thiel,
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ -
Dieter Hoelzer,
Affiliation Goethe University Hospital, Department of Medicine II, Hematology and Oncology, Frankfurt/Main, Germany
⨯ -
Wolf-Karsten Hofmann,
Affiliation University Hospital Mannheim, Department of Hematology and Oncology, Mannheim, Germany
⨯ - [ ... ],
-
Claudia D. Baldus
* E-mail: claudia.baldus@charite.de
Affiliation Charité, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
⨯ - [ view all ]
- [ view less ]
FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors
- Martin Neumann,
- Ebru Coskun,
- Lars Fransecky,
- Liliana H. Mochmann,
- Isabelle Bartram,
- Nasrin Farhadi Sartangi,
- Sandra Heesch,
- Nicola Gökbuget,
- Stefan Schwartz,
- Christian Brandts
- Published: January 24, 2013
- https://doi.org/10.1371/journal.pone.0053190